[Acupoint-injection of BCG polysaccharide nuclear acid for treatment of condyloma acuminatum and its immunoregulatory action on the patient].
OBJECTIVE
To probe into immunological mechanisms and clinical therapeutic effect of acupoint-injection of BCG polysaccharide nuclear acid (BCG-PSN) for treatment of condyloma acuminatum (CA).


METHODS
Two hundred cases were randomly divided into 4 groups. After removed the CA by laser, the treatment group (group A) was treated with acupoint-injection of BCG-PSN, the control group I (group B) with intramuscular injection of BCG-PSN, the control group II (group C) with intramuscular injection of interferon, and the blank control group (group D) with no treatment. The levels of cellular immune function were detected before treatment and after treatment of 6 months, and the cases of relapse were recorded.


RESULTS
The cured rate of 94.3% in the group A was significantly higher than 78.0% in the group B, 80.4% in the group C and 78.2% in the group D, with significant differences (P < 0.05); in the group A, CD4+ percent increased, CD8+ percent decreased, CD4+ /CD+ ratio increased, and NK cell activity increased with a low relapse rate, and with significant differences as compared with the control groups (P < 0.05, P < 0.01).


CONCLUSIONS
Acupoint-injection of BCG-PSN has a better therapeutic effect and it can obviously reduce the recurrence rate of CA. The cellular immunoregulatory action is one of the mechanisms of this therapy in preventing relapse of CA.
Yuan
Shao-ying
SY
Zhuhai Branch of Guangdong Provincial TCM Hospital, Zhuhai 519015, China. ysy017@126.com
Lun
Xin
X
Liu
Dong-sheng
DS
Qin
Zhan
Z
Chen
Wei-tian
WT
D015669:Acupuncture Points; D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000008:administration & dosage*; D016516:CD4-CD8 Ratio; D003218:Condylomata Acuminata / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007267:Injections; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009696:Nucleic Acids / Q000008:administration & dosage; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage
D001500:BCG Vaccine; D009696:Nucleic Acids; D011135:Polysaccharides, Bacterial